Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by:
Marcus Altfeld, M.D., Ph.D.
ClinicalTrials.gov Identifier:
NCT00117429
First received: June 30, 2005
Last updated: February 12, 2010
Last verified: February 2010
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2010
  Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)